Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

The Market and Future Potential for Molecular Point of Care (mPOC) to 2027 - ResearchAndMarkets.com


The "The Market and Future Potential for Molecular Point of Care (mPOC), 2023" report has been added to ResearchAndMarkets.com's offering.

This report is an essential tool for understanding the size and growth opportunity in molecular POC. Molecular point of care (mPOC) has gone from a novel trend to a significant contributor to the market.

The instruments sold by Abbott, BioMerieux, Cepheid and increasingly, a host of other companies, are a significant contributor to the IVD POC market. Knowing these markets is essential to knowing the opportunity in point-of-care testing and microbiology IVD.

The report provides market sizing, forecasting, trend mapping and competitive analysis for point-of-care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings.

The data in The Market and Future Potential for Molecular Point of Care (POC), 2023 includes information on systems and competitor analysis, as well as data on the size and growth of the market:

Many trends are covered in the report, including the role of COVID-19 testing, menu expansion, disease statistics, the COVID-19 crisis, immunoassay competition and enhancement of those competitive POC systems, emerging markets, new journal studies about the efficacy of mPOC, and other trends.

Companies covered in this report, in profiles and/or product tables and market developments discussion include:

Key Topics Covered

Chapter 1: Executive Summary

Chapter 2: Molecular Point-Of-Care Market Development and Trends

Chapter 3: Market Analysis

Chapter 4: Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/bt7reu

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...



News published on and distributed by: